Katerina Chatzidionysiou

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;:ard-2024-225982
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Sebbag E; Lauper K; Molina-Collada J; Aletaha D; Askling J; Gente K; Bertheussen H; Bitoun S; Bolek EC; Burmester GR; Canhao HM; Chatzidionysiou K; Curtis JR; Danlos F-X; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer AC; Schulze-Koops H; Silva-Fernandez L; Szekanecz Z; Buch MH; Finckh A; Gottenberg J-E
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;:643-652
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Sebbag E; Molina-Collada J; Ndoye R; Aletaha D; Askling J; Gente K; Bertheussen H; Bitoun S; Bolek EC; Buch MH; Burmester GR; Canhao HM; Chatzidionysiou K; Curtis JR; Danlos F-X; Guimaraes V; Hetland ML; Iannone F; Kostine M; Kragstrup TW; Kvien TK; Regierer AC; Schulze-Koops H; Sedmak N; Silva-Fernandez L; Szekanecz Z; Lauper K; Finckh A; Gottenberg J-E
Article: ARTHRITIS & RHEUMATOLOGY. 2024;77(3):253-262
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study
Eberhard A; Di Giuseppe D; Askling J; Bergman S; Bower H; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Olofsson T; Frisell T; Turesson C
Article: EUROPEAN JOURNAL OF CANCER. 2024;207:114172
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ; Burgers FH; Janssen JC; Putker AE; Veenstra SPGR; Hospers GAP; Aarts MJB; Hehenkamp KW; Doornebosch VLE; Verhaert M; van den Berkmortel FWPJ; Chatzidionysiou K; Llobell A; Barros M; Maria ATJ; Takeji A; García Morillo J-S; Lidar M; van Eijs MJM; Blank CU; Aspeslagh S; Piersma D; Kapiteijn E; Labots M; Boers-Sonderen MJ; van der Veldt AAM; Haanen JBAG; May AM; Suijkerbuijk KPM
Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: LUPUS. 2024;33(6):615-628
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
Emamikia S; Gomez A; Adahl T; von Perner G; Enman Y; Chatzidionysiou K; Arkema EV; Parodis I
Article: MICROBIOLOGY SPECTRUM. 2024;12(4):e0298123-e02923
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)
Frodlund M; Nived P; Chatzidionysiou K; Soedergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2024;8(2):rkae063
Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years
Curtis JR; Wollenhaupt J; Tas SW; Chatzidionysiou K; Wang L; Roberts K; Tsekouras V
Article: RMD OPEN. 2023;9(4):e003648
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Lindstrom U; Turesson C; Chatzidionysiou K; Lindqvist E; Knight A; Forsblad-d'Elia H; Askling J
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52(6):591-600
Evaluation of an individually tailored smoking-cessation intervention for patients with rheumatoid arthritis in an outpatient clinic
Karlsson M-L; Hertzberg-Nyquist K; Saevarsdottir S; Lundberg IE; Demmelmaier I; Pettersson S; Chatzidionysiou K
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2023;41(10):1985-1990
Original research on Behçet's syndrome: a bibliometric analysis over 20 years (2000-2019)
Bolla E; Chatzidionysiou K; Tektonidou MG; Sfikakis PP
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(16):5377
Intracardiac Thrombi in Morbus Adamantiades-Behcet in Two Swedish Patients
Da Mutten R; Borg A; Chatzidionysiou K; Parodis I
Article: VACCINE. 2023;41(20):3247-3257
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
Frodlund M; Nived P; Chatzidionysiou A; Sodergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
Article: PLOS ONE. 2023;18(12):e0295838
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
Sunden-Cullberg J; Chen P; Habel H; Skorup P; Janols H; Rasmuson J; Niward K; Balkhed AO; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke A; Svensson A-K; Muvva JR; Ljunggren H-G; Horne A-C; Aden U; Henter J-I; Sonnerborg A; Vesterbacka J; Nowak P; Lampa J
Article: RHEUMATOLOGY. 2022;61(10):3952-3962
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindstrom U; Turesson C; Frisell T
Article: SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022;56:152050
Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis
Yang C; Williams RD; Swerdel JN; Almeida JR; Brouwer ES; Burn E; Carmona L; Chatzidionysiou K; Duarte-Salles T; Fakhouri W; Hottgenroth A; Jani M; Kolde R; Kors JA; Kullamaa L; Lane J; Marinier K; Michel A; Stewart HM; Prats-Uribe A; Reisberg S; Sena AG; Torre CO; Verhamme K; Vizcaya D; Weaver J; Ryan P; Prieto-Alhambra D; Rijnbeek PR
Article: RMD OPEN. 2022;8(2):e002465
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
Chatzidionysiou K; di Giuseppe D; Soderling J; Catrina A; Askling J
Article: RHEUMATOLOGY. 2022;61(9):3647-3656
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries
Di Giuseppe D; Lindstrom U; Aaltonen K; Relas H; Provan S; Gudbjornsson B; Hetland ML; Askling J; Kauppi M; Geirsson AJ; Chatzidionysiou K; Jorgensen TS; Dreyer L; Michelsen B; Jacobsson L; Glintborg B
Article: RHEUMATOLOGY. 2022;61(9):3596-3605
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjowall C; Lindqvist E; Askling J
Article: CRITICAL REVIEWS IN IMMUNOLOGY. 2022;42(4):21-36
Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective
Flores-Chavez A; Brito-Zeron P; Retamozo S; Bitoun S; Fisher BA; Liew D; Suijkerbuijk K; Chatzidionysiou K; Suarez-Almazor JM; Lambotte O; Mariette X; Ramos-Casals M
Article: RMD OPEN. 2021;7(3):e001987
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
Bower H; Frisell T; di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(10):1512-1518
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordstrom D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jorgensen TS; Jacobsson LTH; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2021;80(8):1086-1093
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Bower H; Frisell T; Di Giuseppe D; Delcoigne B; Ahlenius G-M; Baecklund E; Chatzidionysiou K; Feltelius N; Forsblad-d'Elia H; Kastbom A; Klareskog L; Lindqvist E; Lindstrom U; Turesson C; Sjowall C; Askling J
Article: RMD OPEN. 2021;7(2):e001662
Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL
Chatzidionysiou K; Circiumaru A; Rethi B; Joshua V; Engstrom M; Hensvold A; af Klint E; Catrina A
Article: RHEUMATOLOGY. 2021;60(2):820-828
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg J-E; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordstrom DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(Suppl 2):247-252
The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future.
Koutsianas C; Chatzidionysiou K
Article: RMD OPEN. 2020;6(2):e001278
Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis
Joshua V; Hensvold AH; Reynisdottir G; Hansson M; Cornillet M; Nogueira L; Serre G; Nyren S; Karimi R; Eklund A; Skold M; Grunewald J; Chatzidionysiou K; Catrina A
Article: RMD OPEN. 2020;6(2):e001363
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordstrom D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2020;38(5):841-847
Validation of new classification criteria of rheumatoid arthritis in an international multicentre study
Li R; Sun X; Ye H; Liu J; Zhao J; Liu X; Mei Y; Zhang Z; Guo J; Bi L; Wang G; Leng X; Gu F; Sun L; Zou Q; Fang Y; Jiang Q; Chatzidionysiou K; Priya S; Janardana R; Nair A; Catrine AI; Danda D; Li ZG
Article: RMD OPEN. 2020;6(2):e001183
Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study.
Najm A; Alunno A; Sivera F; Ramiro S; Haines C; Working Group on Training in Rheumatology across E
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813
Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
Gomez A; Soukka S; Johansson P; Akerstrom E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: ARTHRITIS RESEARCH & THERAPY. 2020;22(1):56
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Panopoulos S; Chatzidionysiou K; Tektonidou MG; Bournia VK; Drosos AA; Liossis S-NC; Dimitroulas T; Sakkas L; Boumpas D; Voulgari PV; Daoussis D; Thomas K; Georgiopoulos G; Vosvotekas G; Sidiropoulos P; Bertsias G; Vassilopoulos D; Sfikakis PP
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):87-91
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C; Flouri I; Fanouriakis A; Nikoloudaki M; Nikolopoulos D; Repa A; Boki K; Chatzidionysiou K; Garyfallos A; Boumpas D; Sidiropoulos P; Bertsias G
Article: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2020;31(1):1-2
Mediterranean Journal of Rheumatology March 2020 Highlights.
Chatzidionysiou K
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20976975
Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
Fragoulis GE; Evangelatos G; Tentolouris N; Fragkiadaki K; Panopoulos S; Konstantonis G; Iliopoulos A; Chatzidionysiou K; Sfikakis PP; Tektonidou MG
Article: RHEUMATOLOGY. 2019;58(12):2170-2176
Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173
Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: JOURNAL OF DIABETES RESEARCH. 2019;2019:2936962-8
Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy
Ekberg NR; Eliasson S; Li YW; Zheng X; Chatzidionysiou K; Falhammar H; Gu HF; Catrina S-B
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(1):17-23
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordstrom D; Canhao H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(6):465-474
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries
Glintborg B; Lindstrom U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordstrom D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jorgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Tormanen MRK; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson LTH
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(2):131-140
Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial
Emamikia S; Gentline C; Chatzidionysiou K; Arnaud L; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2018;5(1):e000287
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
Giannakou I; Chatzidionysiou K; Magder LS; Gyori N; van Vollenhoven R; Petri MA
Article: JOURNAL OF RHEUMATOLOGY. 2017;44(2):162-169
Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration
Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge E-M; Pavelka K; Gabay C; Scherer A; Nordstrom D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Victoria Hernandez M; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
Article: LUPUS SCIENCE & MEDICINE. 2017;4(1):e000192
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
Gyori N; Giannakou I; Chatzidionysiou K; Magder L; van Vollenhoven RF; Petri M
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):314
Differences and similarities in rheumatology speciality training programmes across European countries (vol 74, pg 1183, 2015)
Sivera F; Ramiro S; Cikes N
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):213
Rheumatology training experience across Europe: analysis of core competences
Sivera F; Ramiro S; Cikes N; Cutolo M; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45(sup128):64-75
Optimizing biological treatments for rheumatoid arthritis
Chatzidionysiou K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(7):1336-1342
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Gabay C; Riek M; Hetland ML; Hauge E-M; Pavelka K; Tomsic M; Canhao H; Chatzidionysiou K; Lukina G; Nordstrom DC; Lie E; Ancuta I; Victoria Hernandez M; van Riel PLMC; van Vollenhoven R; Kvien TK
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18:50
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Ancuta I; Pavelka K; Nordstrom DC; Gabay C; Canhao H; Tomsic M; van Riel PLCM; Gomez-Reino J; Kvien TK; van Vollenhoven RF
Article: RHEUMATOLOGY. 2016;55(2):230-236
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge E-M; Pavelka K; Nordstrom DC; Canhao H; Tomsic M; van Vollenhoven R; Gabay C
Article: RMD OPEN. 2016;2(2):e000323
Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
Emamikia S; Arkema EV; Gyori N; Detert J; Chatzidionysiou K; Dougados M; Burmester GR; van Vollenhoven R
Article: RMD OPEN. 2016;2(1):e000133
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Chatzidionysiou K; Turesson C; Teleman A; Knight A; Lindqvist E; Larsson P; Coster L; Forslind K; van Vollenhoven R; Heimburger M
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2015;44(6):431-437
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register
Chatzidionysiou K; Kristensen L-E; Eriksson J; Askling J; van Vollenhoven R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(6):1183-1187
Differences and similarities in rheumatology specialty training programmes across European countries
Sivera F; Ramiro S; Cikes N; Dougados M; Gossec L; Kvien TK; Lundberg IE; Mandl P; Moorthy A; Panchal S; da Silva JAP; Bijlsma JW
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(5):890-896
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R
Journal article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2013;102(3):233-241
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
Journal article: КЛИНИЧЕСКАЯ ПРАКТИКА. 2013;10(3):233-236
Latest developments in the treatment of rheumatoid arthritis: is there new hope for patients?
Chatzidionysiou K; van Vollenhoven R
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2013;42(3):190-195
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
Chatzidionysiou K; van Vollenhoven RF
Article: LANCET. 2012;379(9827):1712-1720
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2012;71(3):374-377
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF; Gabay C
Article: BMJ OPEN. 2012;2(5):e001524
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
Kastbom A; Coster L; Arlestig L; Chatzidionysiou A; van Vollenhoven RF; Padyukov L; Rantapaa-Dahlqvist S; Saevarsdottir S
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(10):1822-1825
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
Raza K; Stack R; Kumar K; Filer A; Detert J; Bastian H; Burmester GR; Sidiropoulos P; Kteniadaki E; Repa A; Saxne T; Turesson C; Mann H; Vencovsky J; Catrina A; Chatzidionysiou A; Hensvold A; Rantapaa-Dahlqvist S; Binder A; Machold K; Kwiakowska B; Ciurea A; Tamborrini G; Kyburz D; Buckley CD
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(9):1575-1580
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordstrom DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Article: ANNALS OF THE RHEUMATIC DISEASES. 2011;70(3):469-475
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam SA; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF
Article: LANCET. 2009;374(9688):459-466
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Coster L; Waltbrand E; Zickert A; Theander J; Thorner A; Hellstrom H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wornert M; Bratt J
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, reumatologi, Karolinska Institutet, 2020
Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2014

Handledning

Marie-Louise Karlsson, The impact of lifestyle changes, and treatment adherence in Early Rheumatoid Arthritis, 2023

Artiklar

Anställningar

Examina och utbildning

Handledning

Nyheter från KI

Kalenderhändelser från KI